Reneo Pharmaceuticals Inc

On March 25, 2024, we provided notice to Leerink Partners LLC (Leerink) of our election to terminate that certain at-the-market equity offering sales agreement with Leerink, dated November 13, 2023 (Sales Agreement), effective as of April 8, 2024. Under the Sales Agreement, we were permitted to offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $100.0 million through Leerink by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act. Prior to such notice of termination, we had not sold any shares of our common stock under the Sales Agreement. In connection with the termination of the Sales Agreement, we terminated the prospectus supplement, dated November 13, 2023, related to the $100.0 million of shares of our common stock issuable pursuant to the terms of the Sales Agreement.